A Phase 2 interventional study of Placebo and Cariprazine in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 72 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-01.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 7th largest by enrollment, is one of 7 that started in 2011, is one of 12 in phase 2, and was the 19th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 819 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 442 across the 53 interventional studies. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
1 of the studies in Depressive Disorder, Major by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07276997AbbVieA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Depressive Disorder, Major by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of meeting DSM-IV-TR criteria for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
Drug: Placebo
Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
Drug: Cariprazine
Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
Drug: Cariprazine
Placebo was supplied in capsules
Cariprazine was supplied in capsules.
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
Time frame: Baseline to Week 8
Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8
The SDS measures an individual's perception of the extent to which his or her emotional symptoms are disrupting his or her functioning in 3 domains, work/school, social life/leisure activities, and family life/home responsibilities. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement.
Time frame: Baseline to Week 8
| Milestone | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg |
|---|---|---|---|
| Started | 269 | 274 | 276 |
| Completed | 234 | 226 | 210 |
| Not completed | 35 | 48 | 66 |
| Withdrew: Protocol deviation | 7 | 10 | 10 |
| Withdrew: Lost to follow-up | 3 | 2 | 5 |
| Withdrew: Withdrawal of consent | 12 | 14 | 15 |
| Withdrew: Adverse event | 8 | 18 | 36 |
| Withdrew: Insufficient therapeutic response | 3 | 4 | 0 |
| Withdrew: Other miscellaneous reasons | 2 | 0 | 0 |
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
| Units on a scale | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg |
|---|---|---|---|
| Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8 | -12.5 ± 0.5 | -13.4 ± 0.5 | -14.6 ± 0.6 |
The SDS measures an individual's perception of the extent to which his or her emotional symptoms are disrupting his or her functioning in 3 domains, work/school, social life/leisure activities, and family life/home responsibilities. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement.
| Units on a scale | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg |
|---|---|---|---|
| Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8 | -6.6 ± 0.5 | -7.7 ± 0.5 | -8.0 ± 0.5 |
Collected over Adverse Events were collected and recorded from the time the participant signs the informed consent form until 30 days after the last dose of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/266 (0%) | 1/266 (0.4%) | 102/266 (38.3%) |
| Cariprazine 1-2 mg | 0/273 (0%) | 0/273 (0%) | 121/273 (44.3%) |
| Cariprazine 2-4.5 mg | 0/273 (0%) | 3/273 (1.1%) | 179/273 (65.6%) |
| Event | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg |
|---|---|---|---|
| DepressionPsychiatric disorders | 1/266 | 0/273 | 0/273 |
| Non-cardiac chest painGeneral disorders | 0/266 | 0/273 | 1/273 |
| AgitationPsychiatric disorders | 0/266 | 0/273 | 1/273 |
| Panic attackPsychiatric disorders | 0/266 | 0/273 | 1/273 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/266 | 0/273 | 1/273 |
| Myocardial ischemiaCardiac disorders | 0/266 | 0/273 | 1/273 |
| Event | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg |
|---|---|---|---|
| AkathisiaNervous system disorders | 6/266 | 18/273 | 61/273 |
| InsomniaPsychiatric disorders | 17/266 | 27/273 | 38/273 |
| HeadacheNervous system disorders | 36/266 | 24/273 | 24/273 |
| NauseaGastrointestinal disorders | 13/266 | 19/273 | 35/273 |
| FatigueGeneral disorders | 11/266 | 18/273 | 27/273 |
| SomnolenceNervous system disorders | 14/266 | 24/273 | 27/273 |
| RestlessnessPsychiatric disorders | 7/266 | 22/273 | 23/273 |
| TremorNervous system disorders | 4/266 | 13/273 | 21/273 |
| DiarrhoeaGastrointestinal disorders | 14/266 | 8/273 | 8/273 |
| ConstipationGastrointestinal disorders | 5/266 | 6/273 | 14/273 |
The Safety Population consisted of all subjects in the Randomized Population who received at least 1 dose of double-blind investigational product.
| Age, Continuous(years) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| Mean | 46.4 ± 11.6 | 45.5 ± 11.9 | 45.1 ± 11.4 | 45.7 ± 11.6 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| Female | 190 | 187 | 201 | 578 |
| Male | 76 | 86 | 72 | 234 |
| Race/Ethnicity, Customized(participants) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| White | 230 | 234 | 242 | 706 |
| All other races | 36 | 39 | 31 | 106 |
| Black or African American | 32 | 31 | 24 | 87 |
| Asian | 1 | 4 | 4 | 9 |
| American Indian or Alaska Native | 2 | 1 | 1 | 4 |
| Other | 1 | 3 | 2 | 6 |
| Race/Ethnicity, Customized(participants) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 17 | 22 | 53 |
| Not Hispanic or Latino | 252 | 256 | 251 | 759 |
| Weight(kg) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| Mean | 81.53 ± 16.19 | 79.69 ± 16.31 | 82.17 ± 17.37 | 81.13 ± 16.65 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| Mean | 28.93 ± 5.09 | 28.21 ± 5.51 | 29.05 ± 5.59 | 28.73 ± 5.41 |
| Waist Circumference(cm) | Placebo | Cariprazine 1-2 mg | Cariprazine 2-4.5 mg | Total |
|---|---|---|---|---|
| Mean | 94.32 ± 13.44 | 93.36 ± 14.20 | 94.91 ± 14.66 | 94.20 ± 14.12 |
Ran from Dec 2011 to primary completion in Dec 2013, 23 months.
Results were first posted in May 2018, 4 years 4 months after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 23 months is above that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine